Market Closed -
Canadian Securities Exchange
03:42:29 2024-04-08 pm EDT
|
5-day change
|
1st Jan Change
|
0.005
CAD
|
0.00%
|
|
0.00%
|
-66.67%
|
Fiscal Period: oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
48.46
|
116.1
|
63.95
|
51.02
|
32.07
|
14.15
|
Enterprise Value (EV)
1 |
47.29
|
104.6
|
61.05
|
58
|
43.61
|
18.68
|
P/E ratio
|
-6
x
|
-8.21
x
|
-7.43
x
|
-0.79
x
|
-1.26
x
|
-0.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
32,568,236
x
|
7,745,708
x
|
3,628,753
x
|
1,084,583
x
|
474,760
x
|
EV / Revenue
|
-
|
29,338,974
x
|
7,393,832
x
|
4,125,740
x
|
1,474,984
x
|
626,876
x
|
EV / EBITDA
|
-7.05
x
|
-9.76
x
|
-17.4
x
|
-4.72
x
|
-4.9
x
|
-4.11
x
|
EV / FCF
|
-11.3
x
|
-9.06
x
|
-9.2
x
|
-3.23
x
|
23.7
x
|
4.94
x
|
FCF Yield
|
-8.83%
|
-11%
|
-10.9%
|
-31%
|
4.22%
|
20.2%
|
Price to Book
|
4.42
x
|
1.59
x
|
0.99
x
|
0.94
x
|
0.8
x
|
0.68
x
|
Nbr of stocks (in thousands)
|
201,919
|
473,718
|
473,718
|
784,879
|
916,206
|
943,009
|
Reference price
2 |
0.2400
|
0.2450
|
0.1350
|
0.0650
|
0.0350
|
0.0150
|
Announcement Date
|
2/27/19
|
2/28/20
|
3/1/21
|
5/11/22
|
2/28/23
|
2/29/24
|
Fiscal Period: oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
3.564
|
8.256
|
14.06
|
29.57
|
29.79
|
EBITDA
1 |
-6.704
|
-10.71
|
-3.509
|
-12.28
|
-8.897
|
-4.542
|
EBIT
1 |
-6.714
|
-12.71
|
-6.494
|
-18.42
|
-12.62
|
-8.059
|
Operating Margin
|
-
|
-356.76%
|
-78.65%
|
-131.03%
|
-42.69%
|
-27.05%
|
Earnings before Tax (EBT)
1 |
-6.671
|
-14.86
|
-9.851
|
-60.47
|
-26.92
|
-21.32
|
Net income
1 |
-6.431
|
-12.77
|
-8.633
|
-57.45
|
-24.24
|
-20.1
|
Net margin
|
-
|
-358.45%
|
-104.56%
|
-408.65%
|
-82%
|
-67.45%
|
EPS
2 |
-0.0400
|
-0.0298
|
-0.0182
|
-0.0824
|
-0.0278
|
-0.0214
|
Free Cash Flow
1 |
-4.173
|
-11.54
|
-6.638
|
-17.96
|
1.84
|
3.779
|
FCF margin
|
-
|
-323.87%
|
-80.4%
|
-127.75%
|
6.22%
|
12.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/19
|
2/28/20
|
3/1/21
|
5/11/22
|
2/28/23
|
2/29/24
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
6.99
|
11.5
|
4.53
|
Net Cash position
1 |
1.17
|
11.5
|
2.91
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.5688
x
|
-1.297
x
|
-0.9979
x
|
Free Cash Flow
1 |
-4.17
|
-11.5
|
-6.64
|
-18
|
1.84
|
3.78
|
ROE (net income / shareholders' equity)
|
-67.8%
|
-30.7%
|
-12.2%
|
-93.1%
|
-50.9%
|
-66.1%
|
ROA (Net income/ Total Assets)
|
-40.4%
|
-14.9%
|
-4.61%
|
-12.7%
|
-8.95%
|
-7.5%
|
Assets
1 |
15.92
|
85.65
|
187.1
|
452.2
|
270.8
|
267.8
|
Book Value Per Share
2 |
0.0500
|
0.1500
|
0.1400
|
0.0700
|
0.0400
|
0.0200
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0
|
0
|
0.0100
|
0
|
Capex
1 |
4.48
|
8.92
|
1.35
|
1.93
|
1.07
|
0.49
|
Capex / Sales
|
-
|
250.17%
|
16.3%
|
13.73%
|
3.62%
|
1.63%
|
Announcement Date
|
2/27/19
|
2/28/20
|
3/1/21
|
5/11/22
|
2/28/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -66.67% | 3.71M | | +35.04% | 5.92B | | -15.13% | 4.51B | | -9.75% | 3.15B | | +2.14% | 3.1B | | -6.82% | 2.42B | | +47.87% | 1.97B | | -7.89% | 1.68B | | +0.09% | 1.65B | | -12.97% | 1.53B |
Alternative Medicine
|